Empagliflozin (Jardiance): A Patient-Friendly Guide
Empagliflozin, also known by the brand name Jardiance, is a prescription medicine in the SGLT2 inhibitor class. It lowers blood sugar in adults with type 2 diabetes and may help reduce the risk of certain heart and kidney complications in selected people with type 2 diabetes.
Empagliflozin is usually taken once daily and can help lower blood sugar, but it is not insulin and is not used to treat type 1 diabetes. Because it can cause serious, uncommon side effects, follow your prescription instructions and talk with your doctor or pharmacist about whether it is right for you.
Key facts at a glance
- ATC
- A10BK03
- Generic
- Empagliflozin
- Class
- sglt2-inhibitor
- Brands
- Jardiance
- Availability
- rx
- Pregnancy
- C
- Lactation
- unsafe
- Half-life (h)
- 12
- Onset (min)
- 60
- Duration (h)
- 24
- Routes
- oral
- Forms
- tablet
- Regions
- CN, US, EU, JP
- Monitoring
- blood-glucose, blood-pressure, genital-infection
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 10mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 10mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 10mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second trimesteravoid
discontinue use during second trimester
regular fetal monitoring and growth assessments
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
third trimesteravoid
discontinue before third trimester due to risk of volume depletion
fetal monitoring and assessment of amniotic fluid volume
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingdiscontinue breastfeeding or avoid drug
avoid empagliflozin while breastfeeding - excreted in breast milk in animals
monitor infant for hypoglycemia and feeding issues
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderly 65 and olderstart with low dose and titrate slowly
use with caution due to increased risk of volume depletion and renal impairment
monitor renal function and volume status regularly
Use with caution and monitor for adverse effects.
pediatric_age
under 18 yearsnot recommended
not approved for use in patients under 18 years of age - safety and efficacy not established
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
severe egfr below 30contraindicated
do not use in patients with severe renal impairment (eGFR < 30 mL/min/1.73m2)
check renal function before initiating and periodically during treatment
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
moderate egfr 30 60dose adjustment may be required
use with caution - monitor renal function every 3-6 months
regular monitoring of eGFR
Use with caution and monitor for adverse effects.
hepatic_impairment
severeuse with caution
limited data in severe hepatic impairment - use only if benefits outweigh risks
monitor liver function and for adverse effects
Use with caution and monitor for adverse effects.
alcohol_users
chronic heavy alcoholavoid excessive alcohol
limit alcohol intake - increases risk of hypoglycemia and volume depletion
monitor blood glucose more frequently
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
FDA approval for Empagliflozin (Jardiance)
Drug class
Sodium-glucose co-transporter-2 inhibitor antidiabetic medication
Common uses
Primary therapeutic indications
Brand name
Primary commercial brand name
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 22, 2026. · Read our editorial policy